These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 15808079)

  • 1. [Caspofungin in the replacement of amphotericin B in the treatment of fungal diseases].
    Yang W; He B
    Zhonghua Yi Xue Za Zhi; 2005 Jan; 85(1):53. PubMed ID: 15808079
    [No Abstract]   [Full Text] [Related]  

  • 2. Caspofungin versus liposomal amphotericin B for empirical therapy.
    Tattevin P; Bareau B; Camus C
    N Engl J Med; 2005 Jan; 352(4):410-4; author reply 410-4. PubMed ID: 15675091
    [No Abstract]   [Full Text] [Related]  

  • 3. Caspofungin versus liposomal amphotericin B for empirical therapy.
    Schneemann M; Imhof A
    N Engl J Med; 2005 Jan; 352(4):410-4; author reply 410-4. PubMed ID: 15675094
    [No Abstract]   [Full Text] [Related]  

  • 4. Caspofungin versus liposomal amphotericin B for empirical therapy.
    Danaher PJ
    N Engl J Med; 2005 Jan; 352(4):410-4; author reply 410-4. PubMed ID: 15675092
    [No Abstract]   [Full Text] [Related]  

  • 5. Caspofungin and amphotericin B for disseminated Fusarium verticillioides in leukemia.
    Makowsky MJ; Warkentin DI; Savoie ML
    Ann Pharmacother; 2005; 39(7-8):1365-6. PubMed ID: 15956243
    [No Abstract]   [Full Text] [Related]  

  • 6. Caspofungin versus liposomal amphotericin B for empirical therapy.
    Jones BL; McLintock LA
    N Engl J Med; 2005 Jan; 352(4):410-4; author reply 410-4. PubMed ID: 15675090
    [No Abstract]   [Full Text] [Related]  

  • 7. New type of effective antifungal treatment identified.
    Bosch X
    Lancet Oncol; 2004 Nov; 5(11):645. PubMed ID: 15536684
    [No Abstract]   [Full Text] [Related]  

  • 8. [Systemic antifungals. Pharmacodynamics and pharmacokinetics].
    Catalán M; Montejo JC
    Rev Iberoam Micol; 2006 Mar; 23(1):39-49. PubMed ID: 16499430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Caspofungin for invasive fungal infections: combination treatment with liposomal amphotericin B in children undergoing hemopoietic stem cell transplantation.
    Pancham S; Hemmaway C; New H; Albert E; Dokal I; Roberts IA; McCloy M
    Pediatr Transplant; 2005 Apr; 9(2):254-7. PubMed ID: 15787803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A cost-effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UK.
    Bruynesteyn K; Gant V; McKenzie C; Pagliuca T; Poynton C; Kumar RN; Jansen JP
    Eur J Haematol; 2007 Jun; 78(6):532-9. PubMed ID: 17419744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.
    Walsh TJ; Teppler H; Donowitz GR; Maertens JA; Baden LR; Dmoszynska A; Cornely OA; Bourque MR; Lupinacci RJ; Sable CA; dePauw BE
    N Engl J Med; 2004 Sep; 351(14):1391-402. PubMed ID: 15459300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trichosporon asahii. Blood-stream infection in a non-cancer patient receiving combination antifungal therapy.
    O'Gorman C; McMullan R; Webb CH; Bedi A
    Ulster Med J; 2006 Sep; 75(3):226-7. PubMed ID: 16964817
    [No Abstract]   [Full Text] [Related]  

  • 13. Comment: caspofungin acetate for treatment of invasive fungal infections.
    Chan J
    Ann Pharmacother; 2003 Apr; 37(4):595. PubMed ID: 12659624
    [No Abstract]   [Full Text] [Related]  

  • 14. An open study of the comparative efficacy and safety of caspofungin and liposomal amphotericin B in treating invasive fungal infections or febrile neutropenia in patients with haematological malignancy.
    Ellis M; Frampton C; Joseph J; Alizadeh H; Kristensen J; Hauggaard A; Shammas F
    J Med Microbiol; 2006 Oct; 55(Pt 10):1357-1365. PubMed ID: 17005784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Caspofungin: a major breakthrough in treatment of systemic fungal infections.
    Agarwal MB; Rathi SA; Ratho N; Subramanian R
    J Assoc Physicians India; 2006 Dec; 54():943-8. PubMed ID: 17334012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological properties and clinical efficacy of a recently licensed systemic antifungal, caspofungin.
    Maschmeyer G; Glasmacher A
    Mycoses; 2005 Jul; 48(4):227-34. PubMed ID: 15982202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The future of antifungal agents].
    Maesaki S
    Rinsho Ketsueki; 2007 Jan; 48(1):26-35. PubMed ID: 17313074
    [No Abstract]   [Full Text] [Related]  

  • 18. Trichosporon asahii infection treated with caspofungin combined with liposomal amphotericin B.
    Bassetti M; Bisio F; Di Biagio A; Pierri I; Balocco M; Soro O; Cruciani M; Bassetti D
    J Antimicrob Chemother; 2004 Aug; 54(2):575-7. PubMed ID: 15231763
    [No Abstract]   [Full Text] [Related]  

  • 19. Caspofungin versus liposomal amphotericin B for empirical therapy.
    Kontoyiannis DP; Lewis RE
    N Engl J Med; 2005 Jan; 352(4):410-4; author reply 410-4. PubMed ID: 15673808
    [No Abstract]   [Full Text] [Related]  

  • 20. [Successful treatment with caspofungin of an invasive candidosis resistant to liposomal amphotericin B in a neutropenic patient].
    Rome A; André N; Michel A; Coze C; Gentet JC; Bernard JL
    Arch Pediatr; 2006 Dec; 13(12):1556-7. PubMed ID: 17049216
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.